Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Stage Adaptive Design, Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal and Thigh Subcutaneous Fat (Stage 2)

NCT04897412 is registered in ClinicalTrials.gov with Caliway Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT04897412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04897412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Stage Adaptive Design, Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal and Thigh Subcutaneous Fat (Stage 2)
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
February 14, 2022
Completion date
March 22, 2023
Enrollment
75 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

subcutaneous fat